Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LVNG RX vs Meto

LVNG RX
Graded #268

Higher grade

vs+0.5
Meto
Graded #278

Lower grade

The verdict

LVNG RX takes it — 62.5/100 to 62/100, but only just.

LVNG RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LVNG RX is a Delaware-registered telehealth platform (LVNG RX LLC) offering compounded semaglutide from $149/mo and tirzepatide from $249/mo, plus a lower-dose GLP-1 microdose program. Meto is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLVNG RX +19
64
45
Dose & formulationLVNG RX +24
64
40
Clinical oversightMeto +32
56
88
Labs & monitoringMeto +23
62
85
FulfillmentLVNG RX +2
69
67
Contract termsLVNG RX +6
61
55
LVNG RX · left barMeto · right bar

The numbers

MetricLVNG RXMeto
WeighScore62.5/10062/100
GradeCC
Scorecard rank#268#278
Semaglutide$149/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (microdose tier, starting dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
LVNG RX

Graded #268 · C

Strengths

  • One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
  • States you are charged nothing if a provider does not approve you for treatment
  • Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
  • Semaglutide from $149/mo is competitive against the wider compounded market
  • Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide

Where it loses points

  • Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
  • Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
  • Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
  • The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
  • No compounding pharmacy, medical group or individual clinician is named anywhere on the site
Meto

Graded #278 · C

Strengths

  • Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
  • Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
  • Matches patients with endocrinologists and obesity medicine specialists within minutes
  • Offers compounded semaglutide and tirzepatide with board-certified physician oversight
  • Handles all prior-auth paperwork; provider location pages exist for all 50 US states

Where it loses points

  • Medication pricing fully gated behind quiz — no public cash price for sema or tirz
  • Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
  • No LegitScript certification or named compounding pharmacy found on any public page
  • Company leadership and clinical team not disclosed publicly
  • Self-pay cash pricing exists per site copy but is not published anywhere

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard